The Oncologist, Vol. 9, No. 1, 3342,
February 2004
© 2004 AlphaMed Press
ORIGINAL PAPER Gynecologic Oncology |
Topotecan Dosing Guidelines in Ovarian Cancer: Reduction and Management of Hematologic Toxicity
Deborah K. Armstrong
Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
Correspondence:
Deborah K. Armstrong, M.D., The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, Room 190, 1650 Orleans Street, Baltimore, Maryland 21231, USA. Telephone: 410-614-2743; Fax: 410-955-0125; e-mail: darmstro{at}jhmi.edu
Topotecan dosing considerations and alternative dosing schedules to reduce and manage myelosuppression during the treatment of relapsed ovarian cancer were reviewed. The myelosuppression patterns from phase I, II, and III clinical trials were analyzed to evaluate the degree of hematologic toxicity and to determine risk factors predictive of myelosuppression. Additionally, recent publications of alternative topotecan doses and schedules were examined. Extent of prior therapy, prior platinum therapy (particularly carboplatin), advanced age, impaired renal function, and prior radiation therapy were identified as potential risk factors for greater hematologic toxicity after topotecan therapy. Reducing the starting topotecan dose to 1.0 or 1.25 mg/m2/day is recommended to reduce the incidence of severe myelosuppression in high-risk individuals receiving topotecan for 5 consecutive days. Hematopoietic growth factors, transfusion therapy, and schedule adjustments may also help manage myelosuppression. Alternative schedules of 3-day or weekly dosing appear to have less myelotoxicity and are currently under evaluation. The clinical aspects of topotecan-related myelosuppression and results from clinical trials indicate that the dose, and possibly the dosing schedule, of topotecan can be modified to reduce hematologic toxicity and improve tolerance without compromising efficacy. Prospective individualization of topotecan dosing may prevent or minimize dose-limiting myelosuppression and allow patients to achieve the maximum topotecan benefit by improving their ability to complete therapy with fewer treatment delays. Ongoing clinical trials evaluating alternative dosing schedules with superior hematologic tolerability may facilitate the inclusion of topotecan in combination regimens for patients with ovarian cancer. Proposed topotecan dosing guidelines to reduce and manage myelosuppression are outlined.
Key Words. Bone marrow/drug effects • Drug toxicity • Ovarian neoplasms • Topotecan
This article has been cited by other articles:

|
 |

|
 |
 
J. Sehouli, D. Stengel, G. Oskay-Oezcelik, A. G. Zeimet, H. Sommer, P. Klare, M. Stauch, A. Paulenz, O. Camara, E. Keil, et al.
Nonplatinum Topotecan Combinations Versus Topotecan Alone for Recurrent Ovarian Cancer: Results of a Phase III Study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
J. Clin. Oncol.,
July 1, 2008;
26(19):
3176 - 3182.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Lichtman, H. Wildiers, E. Chatelut, C. Steer, D. Budman, V. A. Morrison, B. Tranchand, I. Shapira, and M. Aapro
International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patients--An Analysis of the Medical Literature
J. Clin. Oncol.,
May 10, 2007;
25(14):
1832 - 1843.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. T. Morgan, Y. Nakanishi, D. J. Kroll, A. P. Griset, M. A. Carnahan, M. Wathier, N. H. Oberlies, G. Manikumar, M. C. Wani, and M. W. Grinstaff
Dendrimer-Encapsulated Camptothecins: Increased Solubility, Cellular Uptake, and Cellular Retention Affords Enhanced Anticancer Activity In vitro
Cancer Res.,
December 15, 2006;
66(24):
11913 - 11921.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Fischer, E. Thiel, H.-A. Klasen, J. Birkmann, K. Jahnke, P. Martus, and A. Korfel
Prospective trial on topotecan salvage therapy in primary CNS lymphoma
Ann. Onc.,
July 1, 2006;
17(7):
1141 - 1145.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Stewart
Foreword--New Directions for Topotecan in Lung Cancer Treatment
Oncologist,
December 1, 2004;
9(suppl_6):
1 - 3.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ardizzoni
Topotecan in the Treatment of Recurrent Small Cell Lung Cancer: An Update
Oncologist,
December 1, 2004;
9(suppl_6):
4 - 13.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 by AlphaMed Press.
|
|